cbdMD (YCBD) announced that it has entered into securities purchase agreements with institutional investors whereby company issued the investors an aggregate of 1M shares of Series C convertible preferred stock in consideration of gross proceeds to the company of $2.25M. The company intends to use the net proceeds of approximately $2.1M for working capital general corporate purposes and support ongoing strategic initiatives. The Series C shares have a 10% annual dividend and are convertible at the option of the holder into the company’s common stock at an initial conversion price of $2.25 per share, subject to certain anti-dilution protection provisions, with rights and preferences substantially the same as the company’s issued and outstanding Series B convertible preferred stock.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YCBD:
